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Transcription of the Escherichia coli biotin (bio)
operon is regulated by BirA, a protein that is not
only the repressor that regulates bio operon expres-
sion by DNA binding but also the enzyme that cova-
lently attaches biotin to its cognate acceptor
proteins. Binding of BirA to the bio operator requires
dimerization of the protein that is triggered by BirA-
catalyzed synthesis of biotinoyl-adenylate (bio-
AMP), the obligatory intermediate of the attachment
reaction. The current model postulates that the
unmodified acceptor protein binds the monomeric
BirA:bio-AMP complex and thereby blocks assembly
(dimerization) of the form of BirA that binds DNA. We
report that expression of fusion proteins that carry
synthetic biotin-accepting peptide sequences was
as effective as the natural acceptor protein in dere-
pression of bio operon transcription. These peptide
sequences have sequences that are remarkably
dissimilar to that of the natural acceptor protein,
and our data thus argue that the regulatory switch
does not require the extensive protein-protein inter-
actions postulated in the current model.
INTRODUCTION
Biotin (vitamin H) is an enzyme cofactor required for central
metabolism throughout the biological world. The cofactor is a
component of essential carboxylases and decarboxylases
whose function requires covalent attachment of biotin to the
enzyme protein (the free form of biotin is not a physiologically
relevant enzyme cofactor). Biotin protein ligases (BPLs) are the
enzymes that attach biotin to its cognate enzymes (Figure 1A),
and a single ligase is responsible for biotinylation of the 3-amino
group of a specific lysine residue of each of the biotin-dependent
enzymes of an organism (Chapman-Smith and Cronan, 1999). In
mammals, biotin is an essential nutrient, whereas plants, most
bacteria, and most fungi synthesize the vitamin. The biotin
synthetic pathway is long and metabolically expensive, and,
thus, tight regulation of biotin synthesis is expected. In Escheri-
chia coli, expression of the biotin synthetic (bio) operon isChemistry & Biology 17,controlled by a simple, yet remarkably sophisticated, regulatory
system in which the rate of operon transcription responds not
only to the supply of biotin but also to the supply of the enzyme
proteins (called biotin acceptor proteins) that become modified
by covalent attachment of biotin (Beckett, 2007; Chapman-
Smith and Cronan, 1999; Cronan, 1989). This regulatory system
is understood in considerable detail as the result of a combina-
tion of genetic, physiological, biochemical, and biophysical
investigations and provides a striking example of a transcrip-
tional regulatory protein (BirA) that is also an enzyme—in this
case, the BPL that catalyzes the covalent attachment of biotin
to the essential fatty acid synthetic protein, AccB. Moreover,
regulation of the E. coli biotin operon is probably the best under-
stood example of transcriptional regulation by an enzyme unre-
lated to nucleic acid metabolism. The biotin regulatory system
superficially resembles the classic TrpR regulation of the E. coli
tryptophan operon, where the Trp repressor protein binds to
the trpEDCBA operator only when complexed with the core-
pressor, tryptophan. However, in bio operon regulation, the
repressor (called BirA in E. coli) is also the sole cellular BPL,
and the corepressor is not biotin but biotinoyl-50-AMP (bio-
AMP), the product of the first partial reaction of BirA catalysis
(Figure 1) (Beckett, 2007; Chapman-Smith and Cronan, 1999;
Cronan, 1989; Prakash and Eisenberg, 1979). Thus, BirA cata-
lyzes synthesis of its regulatory ligand. It is these novel features
that give this regulatory system its sophisticated properties. It
should be noted that a distantly related bacterium, Bacillus sub-
tilis, is reported to similarly regulate its biotin synthetic pathway
(Bower et al., 1995, 1996), and bioinformatic analyses argue
that this regulatory system is widespread in bacteria (Rodionov
et al., 2002).
In the general model of BirA regulation (Figure 1B), the
maximal rates of E. coli bio operon transcription (derepression)
occur when the biotin supply is severely limited (e.g., biotin star-
vation) or when high levels of a biotin acceptor protein are
present (Beckett, 2007; Chapman-Smith and Cronan, 1999;
Cronan, 1989). Under these conditions, any bio-AMP synthe-
sized is rapidly consumed in biotinylation of the acceptor
proteins (AccB), and, thus, the BirA:bio-AMP complex cannot
accumulate. Hence, BirA remains largely monomeric, and
transcription is maximal because the bio operator is seldom
occupied (Figure 1C). When all of the available AccB has been
biotinylated, newly synthesized biotin-AMP remains bound in
the BirA active site and the BirA:bio-AMP complex accumulates11–17, January 29, 2010 ª2010 Elsevier Ltd All rights reserved 11
Figure 1. The Biotin Protein Ligase (BPL) Reaction and the General Model of bio Operon Regulation
(A) Biotin is attached to small (60–80 residues) well-conserved domains that are generally found at the C termini of the acceptor proteins.
(B and C) General model of repression and derepression of E. coli bio operon transcription by AccB supply. Green ovals denote BirA, tailed blue ovals are AccB,
black dots are biotin, and black dots with red pentagons are bio-AMP.
(B) Under conditions of low AccB synthesis, such as slow-growing cells, the BirA:bio-AMPmonomeric complex accumulates resulting in dimerization. The dimers
bind the operator DNA and repress transcription.
(C) Under conditions where the AccB synthetic rate is high, the monomeric BirA:bio-AMP complex does not accumulate because of biotinylation of AccB to give
the active protein. Hence, dimerization does not occur and the bio promoters remain free to bind RNA polymerase. The bio genes are transcribed to produce
the biotin biosynthetic proteins, which act to replace the biotin consumed in biotinylation and thereby match biotin synthesis to its consumption in protein
biotinylation (Beckett, 2007).
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the biotin operon, resulting in repression of biotin biosynthetic
gene transcription (Figure 1B). The two conditions that result in
derepression therefore act by a common mechanism in that
both result in decreased levels of the BirA:bio-AMP complex
required for binding the bio operator. However, it should be
noted that, of the two regulatory ligands, biotin and AccB, the
latter plays the key regulatory role in vivo because it allows biotin
synthesis to match AccB synthesis (James and Cronan, 2004;
Li and Cronan, 1993). Note that AccB and AccB-87, the last 87
residues of the protein that comprises the biotinylation domain,
are used in their formal sense, as the primary translation prod-
ucts unmodified by biotin attachment.
The mechanism whereby accumulation of the unmodified
biotin domain leads to increased transcription of the bio operon
remains unclear. What is the mechanism of the regulatory switch
and how is it triggered? The current model, that of Weaver et al.
(2001) (Figure 2A), postulates that the unmodified acceptor
protein binds a monomeric BirA:bio-AMP complex and thereby
competes with formation of the dimeric complex, the species
required for effective repression. The BirA surface used to form
the heterodimer is proposed to be extensive and to be the
same surface used in forming the BirA homodimer (Weaver
et al., 2001). Hence, in this model, competing protein-protein
interactions are responsible for derepression triggered by accu-
mulation of unmodified biotin acceptor domains. Implicit in this
model is that the heterodimer must be sufficiently long lived to
compete with homodimerization of BirA:bio-AMP, and, thus, as
in the case of the homodimer, direct detection of the heterodimer
might be expected. However, direct detection of the postulated
AccB plus BirA:bio-AMP heterodimer has not been reported and
only indirect evidence for its existence is available (Zhao and
Beckett, 2008). In our view, this is a major caveat to the model.12 Chemistry & Biology 17, 11–17, January 29, 2010 ª2010 ElsevierAn argument against the competing protein-protein interactions
model is that the time scale of enzyme substrate interactions is
generally short, such that the lifetime of the postulated hetero-
dimer would so brief that its formation could not effectively
compete with BirA homodimer formation. However, enzyme-
substrate interactions can be relatively long lived (Frieden,
1970, 2008).
We expected that a strong test of the competing protein-
protein interaction model would be provided by the small
peptide substrates that undergo BirA-catalyzed biotinylation iso-
lated from peptide libraries by Schatz (1993) as a biotechnology
tool. When fused to either end of a wide variety of proteins, these
sequences of 14 to 30 residues are efficiently biotinylated by BirA
(Cull and Schatz, 2000; Schatz, 1993). Surprisingly, these
peptides have sequences remarkably unlike that of the natural
substrate, AccB (Figure 2B). Indeed, although certain peptide
library residues were fixed to match those bracketing the AccB
lysine residue that becomes biotinylated, many of these residues
failed to survive the selection for biotinylation (Schatz, 1993).
Despite the lack of sequence similarity to AccB, one of these
peptides (peptide 85–14) was shown to be as active a biotin
acceptor as AccB-87 (Beckett et al., 1999), which, in turn, is as
good an acceptor as full-length AccB (Nenortas and Beckett,
1996). The lack of sequence conservation with AccB argues
strongly that these peptide sequences bind to BirA by modes
that differ markedly from that used by AccB. Compelling support
for this argument comes from reports that ligases from other
prokaryotic organisms (B. subtilis and the archaeon, Methano-
coccus jannaschii) and from eukaryotes (the yeast, plant, insect,
and human enzymes) are unable to biotinylate peptide 85 fusion
proteins (Chen et al., 2007; deBoer et al., 2003; Duffy et al., 1998;
Grosveld et al., 2005; Kaikkonen et al., 2008; Slavoff et al., 2008;
Tissot et al., 1998), whereas each of these ligases modifies AccBLtd All rights reserved
Figure 2. The Competing Protein Interactions
Model of the Biotin Operon Regulatory Switch
and Alignments of Biotin-Accepting Sequences
(A) Shown are the regulatory effects engendered by
differing levels of AccB expression. Green ovals denote
BirA, tailed blue ovals are AccB, black dots are biotin,
and black dots with red pentagons are bio-AMP. In the
competing protein-protein interaction model, a BirA:bio-
AMP monomer is proposed to interact with AccB and
thereby inhibit dimerization of the BirA:bio-AMP complex,
the species required for DNA binding (Beckett, 2007).
When the rate of AccB synthesis and demand for biotin
decreases, BirA:bio-AMP dimers accumulate and repress
bio operon transcription.
(B) Alignment of the residues neighboring the biotin
attachment site (asterisk) of E. coli AccB and the five biotin
acceptor proteins from species whose BPLs are reported
to biotinylate E. coli AccB, but not peptide 85 fusion
proteins. For comparison, the sequences of peptides 85
and ME are also given. Residues conserved in at least
four of the sequences are boxed. The natural sequences
are as follows: Ec, E. coli AccB; Bs, Bacillus subtilis
AccB: Mj, Methanocaldococcus jannaschii pyruvate
carboxylase; Sc, Saccharomyces cerevesiae pyruvate
carboxylase 1; At, Arabidopsis thaliana AccB; and Hs,
Homo sapiens pyruvate carboxylase. Note that the in the
libraries that yielded the two peptide sequences of
interest, the codons of the conserved alanine residue
located two resides upstream of the biotinylated lysine
together with the upstream and downstream glutamate
residues were 97% enriched.
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Polyak et al., 2001; Tissot et al., 1998). It seems clear that the
Schatz peptide sequences cannot adopt structures similar to
that of AccB; otherwise, they would act as general BPL sub-
strates. Moreover, because of the short lengths of the acceptor
peptide sequences, the extended interactions proposed for the
AccB-BirA interface would be impossible. Therefore, if extensive
protein-protein interactions are required for derepression of bioChemistry & Biology 17, 11–17, January 2operon transcription, then expression of Schatz
peptide fusion proteins should result in little or
no increase in bio operon expression. On the
other hand, if the fusion proteins were effective
in derepression, this would argue that com-
peting protein-protein interactions are not the
regulatory switch and that the switch mecha-
nism must lay elsewhere. We report that
in vivo production of fusion proteins containing
the peptide 85 sequence or a second Schatz
peptide sequence both resulted in powerful
and efficient derepression of biotin operon
expression.
RESULTS
Our experimental system consisted of two
maltose-binding protein (MBP) fusion proteins
in which either the 15-mer version of the peptide
85 sequence, which we call Pep-85 (Schatz,
1993), or an unnamed peptide later describedby Cull and Schatz (2000), which we call Pep-ME, comprised
the carboxyl termini of the fusion proteins (Figure 2B). We also
tested the peptide 8 sequence (Schatz, 1993), but these anal-
yses were compromised by intracellular degradation of the
fusion protein and will not be further discussed. A control
plasmid in which the AccB-87 sequence was similarly fused to
MBP was also constructed (the MBP constructs lack the peri-
plasmic targeting sequence and thus are cytosolic proteins).9, 2010 ª2010 Elsevier Ltd All rights reserved 13
Figure 3. Derepression of bio Operon Transcrip-
tion by Expression of Biotin-Accepting Proteins
(A) In host strain CY1740, which carries the f(bioFC-
lacZ)501 fusion, the lacZ and lacY genes are fused to the
rightward bio promoter (that of bioBFCD), resulting
a lactose-positive phenotype when bio operon transcrip-
tion is derepressed and a lactose-negative phenotype
when the operon is repressed. This strain also carries
a deletion of the chromosomal lactose operon and is a
biotin auxotroph because of the insertion of the lactose
utilization genes into bioF. The host strain was trans-
formed with either the empty vector plasmid or plasmids
encoding the Pep-ME, Pep-85, or AccB-87 fusion
proteins. Also included was a strain CY1740 derivative
that carried a plasmid encoding a mutant AccB-87 fusion
protein (K122M) in which the lysine targeted for biotinyla-
tion had been replacedwithmethionine. Four independent
transformants from each transformation were patched
onto an LB-ampicillin plate that was incubated at 37C
for 8 hr. The cells were then transferred by replica plating
to a plate of MacConkey agar supplemented with 100 nM
biotin (115 nM total) and ampicillin. After overnight
incubation at 37C, derepression of bio operon transcrip-
tion results in bright red colonies as a result of lactose
utilization, whereas repressed colonies remain colorless
because of their inability to metabolize lactose.
(B) Expression at various biotin concentrations of deriva-
tives of strain CY1740 carrying plasmids encoding
maltose binding protein fusions to biotin accepting peptides 85 (-) or ME (d). The maltose-binding protein fusion to AccB-87 (:) and the vector plasmid encod-
ing amaltose-binding protein that lacked a fusion partner (A) are also shown. b-Galactosidase activities were assayed 4 hr after induction of the maltose-binding
protein fusions with IPTG (1 mM). Note that the abscissa is a logarithmic scale.
(C) Reproducibility of derepression. Four independent transformants from each of the above transformations were streaked on minimal medium plates supple-
mented with 100 nM biotin. Colonies from these plates were then used to inoculate overnight cultures on the samemedium, which, in turn, were diluted 1:100 into
fresh medium containing 100 nM biotin and IPTG. These cultures were allowed to grow to late log phase prior to b-galactosidase assays. Error bars denote the
standard error of the mean.
(D) Biotin attachment to the fusion proteins. Biotinylation of the acceptor proteins was assayed by incorporation of [3H]-biotin into trichloroacetic acid insoluble
material (Abdel-Hamid and Cronan, 2007; Chapman-Smith et al., 1999; Cronan, 1988) 4 hr after IPTG induction of expression of the maltose-binding protein
fusions. In the strain carrying the vector plasmid, the attachment of biotin is to the essential chromosomally encoded AccB protein.
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fusion protein had been inactivated by substituting methionine
for the lysine residue that is the site of biotin attachment was
also constructed.
Fusion to the carboxyl terminus of MBP was chosen because
this was the system that Schatz originally used to analyze his
peptide sequences (Cull and Schatz, 2000; Schatz, 1993), and
biotinylation of a similar MBP-peptide 85 fusion protein has
been studied in vitro (Beckett et al., 1999). These plasmids,
together with the MBP vector plasmid lacking a biotinylation
sequence, were introduced into E. coli CY1740, a strain in which
biotin operon expression drives expression of LacZ b-galactosi-
dase activity (Abdel-Hamid and Cronan, 2007; Barker and
Campbell, 1980). The strain is also a biotin auxotroph (as a result
of insertion of the lac genes into the bio operon), thus permitting
manipulation of intracellular biotin concentrations and labeling
with [3H]-biotin without dilution by endogenously synthesized
biotin (Barker and Campbell, 1980; Cronan, 1988).
The first indication that expression of the two Schatz peptide
fusion proteins gave efficient derepression of bio operon tran-
scription was their behavior on MacConkey indicator plates
containing 115 nM biotin (Figure 3A). The red color of the colo-
nies expressing the biotin accepting peptide sequences or
AccB-87 fusion proteins is to the result of increased transcription
from the bioBFCD promoter that drives expression of the lacZ14 Chemistry & Biology 17, 11–17, January 29, 2010 ª2010 Elsevierand lacY genes. The color is the result of increased transcription
of the bioBFCD promoter, which results in lactose utilization, the
acidic products of which react with indicator dyes in themedium.
In contrast, the same host strain carrying either the empty vector
plasmid or a version of the AccB-87 fusion protein (called
K122M) in which the biotin-accepting lysine residue (K122 of
native AccB) had been changed to methionine gave colorless
colonies, indicating that lactose was not utilized (Figure 3A).
Derepression relative to the vector control was seen upon
expression of the three biotin-accepting fusion proteins over a
100-fold range of biotin concentrations (Figure 3B). At 100 nM
biotin, a concentration that normally fully represses bio operon
transcription (Figure 3B) (Barker and Campbell, 1980; Cronan,
1988), expression of each of the three fusion proteins resulted
in a 200-fold derepression of bio operon expression relative
to the host strain producing the K122M mutant–accepting
protein or the unfused maltose-binding protein (Figure 3C).
Although in a given experiment one of the biotin-accepting fusion
proteins often gave a 10%–20% greater level of derepression
than the others, when assessed over all of our experiments, no
clear pecking order emerged. Because the expression of a
biotin-accepting protein will necessarily deplete intracellular
bio-AMP levels, we also measured the levels of protein biotinyla-
tion in the presence of 100 nM [3H]-biotin (Figure 3D). The
peptide fusion proteins were found to be somewhat moreLtd All rights reserved
Figure 4. Levels of total MBP-Fusion Proteins and
Biotinylated MBP-Fusion Proteins
Polyacrylamide gels (12%) run in the presence of sodium
dodecyl sulfate from two different experiments are shown.
Both sets of cultures were grown with 100 nM biotin.
(A) Detection with anti-MBP antibody. The upper bands
appear to be the product of insufficient denaturation
(dimers?) rather than cross-reacting contaminants
because their apparent sizes vary with those of the major
band in the lane and because in other experiments they
were found to bind streptavidin thereby indicating biotiny-
lation.
(B) Detection by streptavidin binding to the biotinylated
proteins. The fusion proteins are denoted by brackets,
and the migration positions of the molecular weight
markers (Kaleidoscope Protein standard from Bio-Rad)
are given alongside the gels. The AccB band encoded
from the chromosome was not seen at this exposure
because of the abundance of the fusion proteins relative
to AccB plus the competition for biotinylation that results
in decreased biotinylation of AccB (Chapman-Smith
et al., 1999). The electrophoresis time of the gel in panel
A was longer than that of the gel in panel B to increase
resolution. The proteins were transferred to Immobilon-P
membranes (Millipore) and detected as described in
Experimental Procedures.
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operon derepression per protein biotinylation event was calcu-
lated. Western blotting with anti-MBP antibody indicated that
the plasmids encoding the fusion proteins all produced compa-
rable levels of MBP (Figure 4A), and Western blotting with strep-
tavidin also demonstrated biotinylation of all three fusion proteins
(Figure 4B). The high expression level of the fusion proteins was
designed to ensure an excess of unbiotinylated fusion protein. To
test whether this was indeed the case, we performed experi-
ments using unlabeled biotin at 100 nM and then washed the
cells free of biotin. Cell extracts were prepared and incubated
with ATP plus [3H]-biotin to allow biotinylation of any remaining
acceptor protein by the BirA present in the extract. Because
the [3H]-biotin had the same specific activity as that used
in vivo, we could directly calculate the levels of unbiotinylated
acceptor proteins remaining in the cell extracts by comparison
of the in vitro data with those obtained by incorporation of [3H]-
biotin in vivo in a parallel experiment. These experiments showed
that about half of each of the biotin acceptor proteins remained
unbiotinylated in cells grownwith 100 nMbiotin (data not shown).
DISCUSSION
We have shown that two fusion proteins containing synthetic
biotin-accepting sequences are as efficient in derepression of
bio operon transcription as the natural acceptor domain AccB-
87. Therefore, although the competing protein-protein interac-
tions model of BirA transcriptional control has several attractive
features, our data argue that it cannot play an important role in
the regulatory switch. Our conclusions are based on the several
lines of evidence indicating that the Schatz peptide sequences
bind BirA in a markedly different manner than does AccB. The
main lines of evidence are outlined below.
First, as noted in the Introduction, six BPLs from diverse
organisms biotinylate AccB but cannot modify proteins carryingChemistry & Biology 17,the peptide 85 sequence. Because BPLs and their natural
acceptor proteins are generally interchangeable across biology
(Cronan and Reed, 2000), if the peptide 85 sequence mimicked
structural attributes of AccB, the sequence should be biotiny-
lated by BPLs other than BirA. However, BirA is the only ligase
known to biotinylate the peptide 85 sequence.
Second, the Schatz peptides and AccB-87 differ markedly.
Peptides 85 and ME lack the last two of the AccB residues
(residues 122–128) postulated to interact with the main BirA
dimerization surface (Weaver et al., 2001), and no residue other
than the biotinylated lysine is conserved between these peptides
and AccB residues 122–128. Moreover, the other AccB regions
(residues 88–90 and residue 145) thought to be important in
the competing protein-protein interactions model (Weaver
et al., 2001) are absent because they are located outside the
sequences chosen by Schatz in his design of the peptide
libraries. Moreover, a recent crystal structure of a complex of a
biotinylated protein similar to AccB-87 and its cognate BPL
from the archaeon, Pyrococcus horikoshii, shows that, aside
from the biotinylated lysine region, the residue 88–90 region is
the major site of interaction between the two proteins (Bagautdi-
nov et al., 2008). The importance of this region is supported by
the finding that its deletion from natural biotin acceptor proteins
greatly weakens BirA-catalyzed biotinylation (Cronan and Reed,
2000; Leon-Del-Rio and Gravel, 1994). Therefore, the Schatz
peptides would be expected to be very weak biotin acceptors
because they lack the AccB residue 88–90 sequence. However,
as noted above, peptide 85 derivatives are biotinylated as effi-
ciently as is AccB-87, arguing that AccB and the Schatz peptides
must bind BirA by different modes. It should be noted that,
although the peptides ME and 85 have related sequences, the
former peptide lacks the N-terminal glycine of peptide 85,
removal of which causes a severe (10 fold) decrease in the
rate of biotinylation in vitro (Beckett et al., 1999). Because we
find that the fusion proteins containing the two peptide11–17, January 29, 2010 ª2010 Elsevier Ltd All rights reserved 15
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similar biotinylation rates in vivo, it seems possible that even
these two related peptides may bind BirA differently. It should
be noted that circular dichroism spectra (Beckett et al., 1999)
indicate that the 85-14 peptide is unstructured in solution, thus
precluding modeling of its interactions with BirA.
Third, biotinylation of AccB-87 has been shown to be sensitive
to substitutions of the residues neighboring the biotinylated
lysine residue (Reche et al., 1998; Reche and Perham, 1999),
whereas the neighboring residues of the Schatz biotin-accepting
peptides are remarkably diverse (Schatz, 1993). For example,
a glutamate residue positioned three residues before the target
lysine residue is very highly conserved in naturally occurring
biotinylated proteins (Bagautdinov et al., 2008). This residue
makes a hydrogen bond with the main chain nitrogen of a lysine
residue that is thought to be important in recognition of the biotin
domain by BPL (Bagautdinov et al., 2008), and mutagenesis of
this residue in AccB-87 abolishes biotinylation (Chapman-Smith
et al., 1999). In contrast, Schatz isolated biotin-accepting pep-
tides in which arginine, tyrosine, aspartate, asparagine, leucine,
alanine, or threonine were found at this position. Indeed, even in
libraries constructed such that glutamate was strongly favored at
this position, other residues emerged from the selection. In the
most extreme case, a library with 97% glutamate codons at
this position gave biotinylated peptide sequences in which
more than half of modified peptides contained a different residue
at this position (Schatz, 1993). Because some of these residues
have side chains that cannot participate in hydrogen bonding, it
follows that the rules governing biotinylation are markedly
different for AccB and the peptide sequences.
The above discussion aside, it might be argued that the Schatz
peptide sequences are somehow able to form appropriately
long-lived complexes with BirA:bio-AMP that are as effective in
derepression as the postulated complex with AccB. This possi-
bility cannot be totally excluded, but it seems extremely remote.
For this to be the case, the peptides would have tomake interac-
tions with BirA:bio-AMP that have the same binding strengths
and kinetics as that of the natural acceptor protein, despite their
small size and markedly diverged sequences. This seems most
unlikely, particularly because Schatz selected only for the ability
to accept biotin and not for derepression (Schatz, 1993). More-
over, his selections were done in the presence of excess biotin,
which precluded any indirect selection for derepression. Given
our data, we argue that the competing protein-protein interac-
tions postulated in the Beckett model is not the regulatory switch
of the bio operon. What then is the switch? An older model
proposed that bio-AMP levels provide the switch (Cronan,
1989). In that model, the switch was removal of bio-AMP from
the BirA active site by protein biotinylation, and, thus, AccB (or
the Schatz peptides) would act only as classic enzyme sub-
strates in which the interaction between AccB and BirA would
be brief. The acceptor protein would bind, accept a biotin moiety
from the BirA active site, and then rapidly dissociate and leave
the BirA protein as the monomeric form, which would be unable
to dimerize until it could synthesize another molecule of bio-
AMP. Therefore, a high rate of acceptor protein production
would result in a mainly monomeric pool of BirA, and, thus, bio
operon transcription would be derepressed (Zhao and Beckett,
2008). Our data are fully consistent with this model.16 Chemistry & Biology 17, 11–17, January 29, 2010 ª2010 ElsevierNote that BirA is not unique in utilizing small peptides as
efficient biotin acceptors. Peptide sequences have been
selected that are biotinylated by the yeast BPL, but not by
BirA. Consistent with the E. coli results, the sequences these
peptides bear little resemblance to the natural yeast acceptor
domains (Chen et al., 2007).
SIGNIFICANCE
Derepression of bio operon transcription is efficiently trig-
gered by expression of synthetic short nonnative biotin-
accepting peptide sequences, indicating that the regulatory
switch does not depend on the extensive protein-protein
interactions between AccB and the monomeric BirA-bioti-
noyl-AMP complex postulated in the current model.
EXPERIMENTAL PROCEDURES
The growth medium, E. coli strains, and the assays of b-galactosidase activity
and protein biotinylation were as described elsewhere (Abdel-Hamid and
Cronan, 2007). In vitro biotinylation was performed as described elsewhere
(Chapman-Smith et al., 1994). The two Schatz peptide MBP fusion proteins
were constructed using cassettes made by annealing complementary oligonu-
cleotides: 50-AATTCGGAGGACTGAACGACATCTTTGAAGCGCAAAAAATCG
AATGGCATTA plus 50-AGCTTAATGCCATTCGATTTTTTGCGCTTCAAAGATG
TCGTTCAGTCCTCCG for peptide 85 and 50-AATTCGGACTGTGTGACATCT
TCGAATCCCAGAAAATCGAATGGCATTCTGCGTA plus 50-AGCTTACGCAG
AATGCCATTCGATTTTCTGGGATTCGAAGATGTCACACAGTCCG for pep-
tide ME. Annealing of the oligonucleotide pairs resulted in EcoRI and HindIII
sticky ends that were ligated to pMAL-2c-E (New England Biolabs) cut with
the same enzymes to give genes encoding the MBP-peptide fusion proteins.
The MBP-AccB-87 fusion protein was constructed by cutting pCY142 (Reed
and Cronan, 1991) with SalI plus XhoI and ligating the purified AccB-87 frag-
ment to pMAL-2c-E cut with SalI. All constructs were verified by DNA
sequencing. The plasmid encoding the K122M AccB-87 fusion protein was
constructed by replacement of the NcoI-PstI fragment of the plasmid encoding
the MBP-AccB-87 fusion protein with the Nco-NsiI fragment of the plasmid
encoding the K122M mutant form of AccB constructed previously (Abdel-
Hamid and Cronan, 2007). Western blotting with anti-MBP (New England
Biolabs) was done according to the protocol provided with the reagent. The
MBP-protein complexes were detected by the ECL system (Amersham) using
a horseradish peroxidase–coupled sheep anti–mouse IgG (Amersham) as the
secondary antibody, whereas blotting with a streptavidin-enzyme complex
was done as described elsewhere (Choi-Rhee et al., 2004). In both cases,
chemiluminescence detection was done on a Bio-Rad Chemidoc XRS system.
The molecular mass markers were the Precision Plus (Bio-Rad).
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